Pharmacogenetics: a general review on progress to date

Pharmacogenetics is not a new subject area but its relevance to drug prescribing has become clearer in recent years due to developments in gene cloning and DNA genotyping and sequencing. There is a very extensive published literature concerned with a variety of different genes and drugs. There is ge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British medical bulletin 2017-12, Vol.124 (1), p.65-15
1. Verfasser: Daly, Ann K
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 15
container_issue 1
container_start_page 65
container_title British medical bulletin
container_volume 124
creator Daly, Ann K
description Pharmacogenetics is not a new subject area but its relevance to drug prescribing has become clearer in recent years due to developments in gene cloning and DNA genotyping and sequencing. There is a very extensive published literature concerned with a variety of different genes and drugs. There is general agreement that pharmacogenetic testing is essential for the safe use of drugs such as the thiopurines and abacavir. Whether pharmacogenetic testing should be applied more widely including to the prescription of certain drugs such as warfarin and clopidogrel where the overall benefit is less clear remains controversial. Personal genotype information is increasingly being made available directly to the consumer. This is likely to increase demand for personalized prescription and mean that prescribers need to take pharmacogenetic information into account. Projects such as 100 000 genomes are providing complete genome sequences that can form part of a patient medical record. This information will be of great value in personalized prescribing. Development of new drugs targeting particular genetic risk factors for disease. These could be prescribed to those with an at risk genotype.
doi_str_mv 10.1093/bmb/ldx035
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1952525838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1952525838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-e04767d93c27ada861677cd7997c6eb9ae30b304277717ca69d90a66affc24173</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqWw4QOQlwgpdGyndswOVbykSrCAtTWxJyUoaYqd8vh7UhXQLO4sjq6uDmOnAi4FWDUt23LahC9Qsz02FrkRWaGs2GdjADCZyCWM2FFKbwBCKSgO2UhayCGXcsz00yvGFn23pBX1tU9XHPn2j9jwSB81ffJuxdexW0ZKifcdD9jTMTuosEl08psT9nJ78zy_zxaPdw_z60XmlVR9RpAbbYJVXhoMWGihjfHBWGu8ptIiKSjVsMQYI4xHbYMF1BqrystcGDVh57veYcD7hlLv2jp5ahpcUbdJTtiZHK5QxYBe7FAfu5QiVW4d6xbjtxPgtp7c4MntPA3w2W_vpmwp_KN_YtQP6lhi1Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1952525838</pqid></control><display><type>article</type><title>Pharmacogenetics: a general review on progress to date</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Daly, Ann K</creator><creatorcontrib>Daly, Ann K</creatorcontrib><description>Pharmacogenetics is not a new subject area but its relevance to drug prescribing has become clearer in recent years due to developments in gene cloning and DNA genotyping and sequencing. There is a very extensive published literature concerned with a variety of different genes and drugs. There is general agreement that pharmacogenetic testing is essential for the safe use of drugs such as the thiopurines and abacavir. Whether pharmacogenetic testing should be applied more widely including to the prescription of certain drugs such as warfarin and clopidogrel where the overall benefit is less clear remains controversial. Personal genotype information is increasingly being made available directly to the consumer. This is likely to increase demand for personalized prescription and mean that prescribers need to take pharmacogenetic information into account. Projects such as 100 000 genomes are providing complete genome sequences that can form part of a patient medical record. This information will be of great value in personalized prescribing. Development of new drugs targeting particular genetic risk factors for disease. These could be prescribed to those with an at risk genotype.</description><identifier>ISSN: 0007-1420</identifier><identifier>EISSN: 1471-8391</identifier><identifier>DOI: 10.1093/bmb/ldx035</identifier><identifier>PMID: 29040422</identifier><language>eng</language><publisher>England</publisher><ispartof>British medical bulletin, 2017-12, Vol.124 (1), p.65-15</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-e04767d93c27ada861677cd7997c6eb9ae30b304277717ca69d90a66affc24173</citedby><cites>FETCH-LOGICAL-c323t-e04767d93c27ada861677cd7997c6eb9ae30b304277717ca69d90a66affc24173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29040422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daly, Ann K</creatorcontrib><title>Pharmacogenetics: a general review on progress to date</title><title>British medical bulletin</title><addtitle>Br Med Bull</addtitle><description>Pharmacogenetics is not a new subject area but its relevance to drug prescribing has become clearer in recent years due to developments in gene cloning and DNA genotyping and sequencing. There is a very extensive published literature concerned with a variety of different genes and drugs. There is general agreement that pharmacogenetic testing is essential for the safe use of drugs such as the thiopurines and abacavir. Whether pharmacogenetic testing should be applied more widely including to the prescription of certain drugs such as warfarin and clopidogrel where the overall benefit is less clear remains controversial. Personal genotype information is increasingly being made available directly to the consumer. This is likely to increase demand for personalized prescription and mean that prescribers need to take pharmacogenetic information into account. Projects such as 100 000 genomes are providing complete genome sequences that can form part of a patient medical record. This information will be of great value in personalized prescribing. Development of new drugs targeting particular genetic risk factors for disease. These could be prescribed to those with an at risk genotype.</description><issn>0007-1420</issn><issn>1471-8391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNo9kMtOwzAQRS0EoqWw4QOQlwgpdGyndswOVbykSrCAtTWxJyUoaYqd8vh7UhXQLO4sjq6uDmOnAi4FWDUt23LahC9Qsz02FrkRWaGs2GdjADCZyCWM2FFKbwBCKSgO2UhayCGXcsz00yvGFn23pBX1tU9XHPn2j9jwSB81ffJuxdexW0ZKifcdD9jTMTuosEl08psT9nJ78zy_zxaPdw_z60XmlVR9RpAbbYJVXhoMWGihjfHBWGu8ptIiKSjVsMQYI4xHbYMF1BqrystcGDVh57veYcD7hlLv2jp5ahpcUbdJTtiZHK5QxYBe7FAfu5QiVW4d6xbjtxPgtp7c4MntPA3w2W_vpmwp_KN_YtQP6lhi1Q</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Daly, Ann K</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20171201</creationdate><title>Pharmacogenetics: a general review on progress to date</title><author>Daly, Ann K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-e04767d93c27ada861677cd7997c6eb9ae30b304277717ca69d90a66affc24173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daly, Ann K</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British medical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daly, Ann K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacogenetics: a general review on progress to date</atitle><jtitle>British medical bulletin</jtitle><addtitle>Br Med Bull</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>124</volume><issue>1</issue><spage>65</spage><epage>15</epage><pages>65-15</pages><issn>0007-1420</issn><eissn>1471-8391</eissn><abstract>Pharmacogenetics is not a new subject area but its relevance to drug prescribing has become clearer in recent years due to developments in gene cloning and DNA genotyping and sequencing. There is a very extensive published literature concerned with a variety of different genes and drugs. There is general agreement that pharmacogenetic testing is essential for the safe use of drugs such as the thiopurines and abacavir. Whether pharmacogenetic testing should be applied more widely including to the prescription of certain drugs such as warfarin and clopidogrel where the overall benefit is less clear remains controversial. Personal genotype information is increasingly being made available directly to the consumer. This is likely to increase demand for personalized prescription and mean that prescribers need to take pharmacogenetic information into account. Projects such as 100 000 genomes are providing complete genome sequences that can form part of a patient medical record. This information will be of great value in personalized prescribing. Development of new drugs targeting particular genetic risk factors for disease. These could be prescribed to those with an at risk genotype.</abstract><cop>England</cop><pmid>29040422</pmid><doi>10.1093/bmb/ldx035</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1420
ispartof British medical bulletin, 2017-12, Vol.124 (1), p.65-15
issn 0007-1420
1471-8391
language eng
recordid cdi_proquest_miscellaneous_1952525838
source Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title Pharmacogenetics: a general review on progress to date
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T06%3A46%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacogenetics:%20a%20general%20review%20on%20progress%20to%20date&rft.jtitle=British%20medical%20bulletin&rft.au=Daly,%20Ann%20K&rft.date=2017-12-01&rft.volume=124&rft.issue=1&rft.spage=65&rft.epage=15&rft.pages=65-15&rft.issn=0007-1420&rft.eissn=1471-8391&rft_id=info:doi/10.1093/bmb/ldx035&rft_dat=%3Cproquest_cross%3E1952525838%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1952525838&rft_id=info:pmid/29040422&rfr_iscdi=true